Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OYST

Oyster Point Pharma (OYST) Stock Price, News & Analysis

Oyster Point Pharma logo

About Oyster Point Pharma Stock (NASDAQ:OYST)

Advanced Chart

Key Stats

Today's Range
$11.17
$11.17
50-Day Range
$11.08
$11.20
52-Week Range
$3.46
$19.00
Volume
330 shs
Average Volume
212,171 shs
Market Capitalization
$299.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Receive OYST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter.

OYST Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

OYST Stock Analysis - Frequently Asked Questions

Oyster Point Pharma, Inc. (NASDAQ:OYST) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.48. The business earned $17.94 million during the quarter. Oyster Point Pharma had a negative trailing twelve-month return on equity of 490.33% and a negative net margin of 901.99%.

Oyster Point Pharma (OYST) raised $85 million in an IPO on Thursday, October 31st 2019. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oyster Point Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/04/2021
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:OYST
Fax
N/A
Employees
303
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$100.66 million
Net Margins
-901.99%
Pretax Margin
-901.99%

Debt

Sales & Book Value

Annual Sales
$24.54 million
Price / Cash Flow
N/A
Book Value
$3.80 per share
Price / Book
2.94

Miscellaneous

Free Float
22,039,000
Market Cap
$299.85 million
Optionable
Not Optionable
Beta
1.31
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:OYST) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners